Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval for Fenbendazole oral suspension veterinary drug, enhancing its product line and market competitiveness in the veterinary sector [1][3]. Group 1: Approval Information - The product name is Fenbendazole oral suspension with an approval number of Veterinary Drug No. 110807959, valid from April 25, 2025, to April 24, 2030 [1]. - The product is developed in collaboration with 12 companies and is the first approved new veterinary drug of its kind [1]. - Fenbendazole is a benzimidazole anthelmintic used to treat infections in pigs caused by roundworms, esophageal worms, and whipworms [1]. Group 2: Product Development Timeline - The application for the veterinary drug approval was submitted by Haizheng Animal Health Co., Ltd. on January 11, 2025 [1]. Group 3: Market Position and Strategy - The approval of Fenbendazole oral suspension will enrich the company's veterinary drug product line and structure, aiding in the strategic layout of the veterinary drug sector [3].

Core Viewpoint - Zhejiang Hai Zheng Animal Health Products Co., Ltd., a subsidiary of Hai Zheng Pharmaceutical (600267), has received approval from the Ministry of Agriculture and Rural Affairs for its fenbendazole oral suspension veterinary drug, which will enhance the company's product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The approved product is classified as a Category V new veterinary drug, effective from April 25, 2025, to April 24, 2030 [1] - The drug is intended for the treatment of infections caused by pig roundworms, esophageal worms, and whipworms [1] - The application for the approval was submitted on January 11, 2025, indicating a proactive approach by the company in expanding its veterinary product offerings [1]